1. INTRODUCTION:

Global Context of Antimicrobial Resistance:

Antimicrobial resistance, also known as AMR, is considered one of the most serious public health challenges facing the world today. The increase in the number of multidrug-resistant (MDR) Gram-positive pathogens has created a very complex set of options for treating patients both within the community and in hospitals¹. Two examples of these infections that have increased morbidity, mortality, prolonged length of stay in the hospital, and access to healthcare resources are methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). The traditional agents used for the treatment of these types of infections, such as vancomycin and beta-lactams, have decreased effectiveness as a result of adaptive resistance mechanisms, biofilm formation, and altered penicillin-binding proteins². Therefore, the search for new antibiotics with novel molecular targets has become a strategic focus in the field of antimicrobial drug discovery.

Emergence of Oxazolidinones:

The first new synthetic class of antibiotics to be added to the armamentarium of clinicians in many decades was the oxazolidinone class of antibiotics. The oxazolidinones were designed based on the knowledge of how bacteria produce proteins, which allows oxazolidinones to work earlier in the process of inhibiting bacterial protein production than do other antibiotic classes, all of which are derived from naturally produced bile acids. Linezolid received FDA approval in 2000 and has changed the treatment of resistant Gram-positive bacteria. In addition to being effective against resistant Gram-positive bacteria, linezolid also uses a new mechanism of action compared to that of other agents, including macrolides, lincosamides, aminoglycosides, and tetracyclines³.

Rationale and Scope for Review:

While linezolid has been thoroughly investigated for approximately 20 years, new data continues to suggest the following need for review:

· Evidence of new resistance mechanisms (e.g., cfr gene, mutations of 23S rRNA) emerging from clinical use;

· Long-term mitochondrial toxicity;

· Optimizing kil dosages;

· Advantages over new oxazolidinones (e.g., tedizolid);

· Potential usefulness beyond current label in treating TB and other multi-drug-resistant infections.

The goal of this paper is to synthesize a comprehensive view of the chemical, pharmacological, clinical, and resistance aspects of linezolid resp; linezolid for researchers working in fields of medicinal chemistry, pharmacology, infectious diseases and/or antimicrobial stewardship⁴.

2. Chemical Structure and Medicinal Chemistry of Linezolid:

Linezolid belongs to the oxazolidinone category of fully synthetic antibiotics. It has an unusual heterocyclic backbone that can be described in terms of the 2-oxazolidinone framework, which is essential for the pharmacophore that provides its antibacterial effects⁴.

Chemical characteristics: (Hashemian et al., 2018)

· IUPAC Name: (S)-N{{3-{3-fluoro-4-(morpholin-4-yl) phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide.

· Molecular formula: C₁₆H₂₀FN₃O₄

· Molecular weight: 337.35 g/mol

· Chirality: One stereogenic center at the C-5 position of the oxazolidinone ring

· Active configuration: S-enantiomer

Figure 1: Chemical Structure of Linezolid⁴

The correct stereochemistry is essential for efficacy: the S-enantiomer fits best into the ribosomal binding pocket while the R-enantiomer has much lower antibacterial activity.

Linezolid has 4 major structural domains: (1) the oxazolidinone ring (where the antibacterial activity is found), (2) substituted fluorophenyl moiety, (3) morpholine, and (4) acetamide side chain. The oxazolidinone ring is the essential structural core and provides the basis for antibacterial activity. The 2-oxo group on the oxazolidinone ring forms hydrogen bonds with nucleotides located in domain V of the 23S ribosomal RNA of the bacterial 50S ribosome subunit. It is generally true that altering the oxazolidinone ring structure leads to substantially reduced antibacterial activity, indicating that this part of the linezolid structure has vital pharmacophore properties⁵.

The aromatic fluorophenyl group also contributes significantly to the overall antibacterial activity of linezolid. The presence of the meta-fluoro substitution increases the lipophilicity of the compound and increases the binding affinity between the compound and the ribosomal target site. The addition of electron withdrawing substituents to the ring system during lead optimization has been correlated with increased antibacterial activity because they promote beneficial interactions at the ribosomal peptidyl transferase centre; additionally, this substitution pattern has also been shown to enhance the permeability of linezolid across membranes, thereby enhancing linezolid's access to the bacterial target intracellularly⁵.

Pharmacokinetic properties are greatly affected by the morpholine ring. The morpholine ring contributes significantly to the high oral bioavailability (nearly 100% bioavailability is possible) of linezolid due to an increase in aqueous solubility resulting from the associated balanced hydrophilic lipophilic profile and this allows for rapid absorption from the gastrointestinal tract and widespread distribution throughout the body. Any removal or replacement of the morpholine moiety structurally will alter pharmacokinetics as a result reduce linezolid’s clinical usefulness.

The acetamide side chain serves to stabilize overall molecular conformation and provide additional hydrogen bonding interactions to support target affinity. The relative position of this substitution can affect the metabolism and toxicity of linezolid in mitochondria due to this reason should be given specific consideration when optimizing compound in medicinal chemistry.

From a physicochemical perspective, linezolid has properties that would be consistent with orally active compounds that are small. The lipophilic character of linezolid is moderate (approximately 0.5 to 1 log P) and showed good aqueous solubility; only about 30% of plasma protein binding occurs. These characteristics of linezolid allow for predictable systemic exposure, extensive tissue distribution and the establishment of effective concentrations in epithelial lining fluid of lung, skin, and other soft tissues. Furthermore, linezolid does not need to be metabolically activated, and thus will primarily require non-enzymatic oxidation, which eliminates variability typically seen with metabolic activation due to cytochrome P450.

Asymmetric syntheses of oxazolidinone (the core of linezolid) are used to achieve an enantiomeric purity that is overwhelmingly in the S-enantiomer configuration. Typical synthetic strategies for linezolid will use the following steps: the formation of a chiral epoxide as the intermediate; cyclization of this epoxide to yield the oxazolidinone ring; incorporation of the 4-fluorophenyl group on the ring through aromatic substitution reactions; incorporation of the morpholine group; final acetylation of the morpholine substituted oxazolidinone product to yield active linezolid. Manufacturing of linezolid must emphasize scalability, low cost, and the lowest possible levels of racemic impurities. Contemporary synthetic refinements in the production of linezolid employ catalytic asymmetric reactions and green reaction conditions to improve sustainability⁶.

Medicinal chemistry optimization of linezolid was initially directed towards maximizing the antibacterial activity and then towards ensuring selective inhibition of bacterial ribosomes vs mammalian cytosolic ribosomes. There are structural similarities between bacterial and mitochondrial ribosomes that have been linked to some of the adverse effects seen with long-term usage of linezolid. The mechanism by which mitochondrial protein synthesis is inhibited has been shown to cause adverse effects such as lactic acidosis, myelosuppression and peripheral neuropathy that were witnessed during prolonged exposure. These off-target interactions provided the foundation for the structural refinements seen in subsequent generations of oxazolidinones, including tedizolid, in which the goal was to maintain antibacterial activity while improving the safety profiles of these agents⁷.

3. Mechanism of Action and Mechanistic Pharmacology:

Linezolid is a chemically produced antibacterial medication that prevents bacterial protein production by working in a specific way. It works differently than traditional ribosomal inhibitors; instead of inhibiting protein synthesis during elongation or peptide chain movements, it prevents protein production from starting by stopping the first step in translation from occurring.

Additionally, linezolid binds to an area of the 23S rRNA component of the 50S ribosomal subunit known as domain V, specifically the region known as the peptidyl transferase center (PTC) which has been well conserved throughout evolution and is critical to peptide bond (bacterial protein) formation. Data acquired from molecular modeling and crystallographic studies confirm that linezolid interacts with specific PTC nucleotides via hydrogen bonding and hydrophobic interactions, thus inducing conformational change in ribosomes. This change prevents correct placement of the formylmethionyl-tRNA (inactive methionine tRNA) in the P-site and ultimately prevents assembly of the functional 70S initiation complex⁸.

Since the 70S initiation complex is required for initiation of bacterial protein synthesis, halting its formation stops bacterial protein synthesis before elongation has a chance to begin. The result is that linezolid inhibits the formation of all critical bacterial proteins necessary for reproduction.

Linezolid is an antibiotic that is produced in a laboratory and is used to kill bacteria by stopping the production of proteins in bacteria. It works in a different way than the traditional way antibiotics work to kill bacteria (i.e., inhibiting the production of proteins during the elongation of polypeptide chains), but it is active at the site of protein synthesis and prevents new proteins from being produced by preventing translation from taking place⁹.

The mechanism of action for linezolid is binding to a specific location on the 23S rRNA of the 50S ribosomal subunit, known as domain V (specifically at the area of the peptidyl transferase center (PTC) where peptide bonds will form), which is conserved throughout evolution and is essential for forming new peptide bonds. Data from molecular modeling studies and X-ray crystallography demonstrate that linezolid binds to specific nucleotides in the PTC by way of hydrogen bonds and hydrophobic interactions causing a conformational change in the ribosome that prevents the binding of formylmethionyl-tRNA (inactive methionine-tRNA) to the P-site. Therefore, it is impossible for the 70S initiation complex to be formed, thus preventing any new bacterial proteins from being created.

Since the 70S initiation complex is necessary to initiate bacterial protein synthesis (and elongation) and the formation of the initiation complex is prevented by linezolid, no new proteins will be made until the 70S initiation complex is formed. As a result, linezolid prevents the production of all critical bacterial proteins needed for reproduction.

Linezolid, in addition to its antibacterial action, has weak reversible inhibition of monoamine oxidase particularly MAO-A. Although this effect does not contribute directly to antibacterial activity, it has important clinical implications due to potential interactions with other agents (i.e., serotonergic agents and sympathomimetics) that could increase the risk of serotonin syndrome or hypertensive reactions, respectively. The evaluation of this secondary pharmacological effect of linezolid suggests a greater degree of biochemical interaction than what would be expected in relation to its antibacterial action¹⁰.

Another consideration regarding the mechanistic action of linezolid relates to mitochondrial toxicity given that structurally, mitochondrial ribosomes and bacterial ribosomes show similarities; hence prolonged exposure to linezolid will cause inhibition of mitochondrial protein synthesis. Thus, this off-target effect could lead to adverse events such as: Myelosuppression, Peripheral Neuropathy, Optic Neuropathy, and Lactic Acidosis; which all occur during long-term use of linezolid. These toxicities illustrate the importance of maintaining an appropriate balance between antimicrobial potency and safety for the host cell¹¹.

Figure 2: Mechanism of Action at Ribosomal Level¹¹

4. Spectrum of Antibacterial Activity and Resistance Profile:

Linezolid is a potent, specific antibiotic that works against many different types of range of Gram-positive bacteria, especially multi-resistant organisms. It is most clinically important for the treatment of organisms that are resistant to beta-lactam, glycopeptide, and other standard classes of anti-bacterials¹².

Activity Against Gram-positive Pathogens:

Linezolid shows superior efficacy against many clinically important Gram-positive organisms in vitro and in clinical practice. In particular, linezolid has excellent activity against Methicillin Resistant Staphylococcus aureus (both hospital-acquired and community-acquired strains). The methicillin resistance mechanism is related to the altered penicillin binding protein (PBP2a) but does not contribute to resistance to the ribosome target, therefore resistance to methicillin does not affect linezolid's efficacy.

Linezolid also has excellent activity against Vancomycin Resistant Enterococci, specifically Enterococcus faecium strains that have developed resistance to glycopeptides. As with methicillin-resistant strains, linezolid's target is not related to the peptidoglycan synthetic pathway; therefore, linezolid is still effective regardless of whether the organism has vanA or vanB phenotypes.

Linezolid is also active against other Gram-positive bacteria, including:

· Streptococcus pneumoniae (including penicillin-resistant strains)

· Streptococcus pyogenes

· Streptococcus agalactiae

· Coagulase-negative staphylococci

The MIC values for the majority of susceptible Gram-positive organisms range from 0.5 to 2 µg/mL, demonstrating that linezolid has high intrinsic activity¹³.

Limited Gram-Negative Infection Activity:

There is little to no activity of linezolid against most Gram-negative organisms. The primary reason for this lack of activity is due to the presence of an outer membrane in Gram-negative bacteria, which restrict penetration by drugs into the bacteria. Further, efflux pumps and intrinsic barriers to permeability further limit intracellular accumulation of linezolid. Because of this, linezolid is not indicated for infections caused by Enterobacterales, Pseudomonas aeruginosa or Acinetobacter species¹⁴.

Activity Against Atypical and Mycobacterial Organisms:

Linezolid has been shown to have activity against certain atypical and mycobacterial organisms. As such, linezolid has been included in treatment regimens for multidrug-resistant tuberculosis due to Mycobacterium tuberculosis. The effectiveness of linezolid in the treatment of MDR-TB is largely attributable to its ability to inhibit protein synthesis of mycobacteria; however, long-term use increases the risk of mitochondrial toxicity.

Resistance to Linezolid:

Initially, linezolid had low rates of resistance; however, increasing reports of emerging resistance to linezolid continue to be published.

There are three primary resistance mechanisms as follows:

· Point mutations in the 23S rRNA gene:

Point mutations in domain V of the 23S rRNA decrease binding affinity for linezolid because the drug cannot bind to its intended target and therefore does not exhibit its inhibitory effect. These mutations are routinely found in isolates that have had prolonged exposure to linezolid.

· CFR gene-mediated methylation:

The CFR (chloramphenicol – florfenicol resistance) is plasmid-encoded methyltransferase which methylates adenine residues located within the 23S rRNA prevent proper linezolid binding.

Global Resistance Developments:

The resistance rates of Linezolid are still quite low compared with other classes of antibiotics, even though linezolid-resistant strains of MRSA and VRE have been found at times in hospitals. Resistance usually develops after using linezolid for a long time, not using enough medication, or if patients receive too much pressure in the ICU.

While the majority of regions report less than 2-3% resistant isolates based on surveillance studies, the presence of localized outbreaks demonstrates that good antimicrobial stewardship and susceptibility testing are vital functions.

Resistance-Related Clinical Impact:

As linezolid resistance continues to emerge, it limits the number of effective treatment options for people with serious Gram-positive infection. Hence, it is imperative that these new areas of linezolid resistance be detected early using molecular diagnostics and appropriate susceptibility testing; Moreover, to reduce the likelihood of developing resistance, clinicians should optimize pharmacokinetics/pharmacodynamics when prescribing linezolid, avoid unnecessary extended courses of therapy, and implement appropriate antimicrobial stewardship programs¹³.

5. Pharmacokinetics and Pharmacodynamics of Linezolid:

Linezolid has predictable and well-defined pharmacokinetics that facilitate the use of oral and intravenous formulations without requiring dose adjustments during conversion of routes of administration. Linezolid's nearly complete oral bioavailability and linearly proportional pharmacokinetics provide consistent systemic exposure to the drug and thus therapeutic reliability of the drug.

Absorption:

Following oral administration, linezolid is rapidly and completely absorbed (i.e., the bioavailability of linezolid following oral administration approaches 100%). Peak plasma concentrations (C_max) of linezolid are typically reached within 1 to 2 hours of dosing with oral formulations. The absorption of linezolid will be slightly delayed by food; however, the overall amount of linezolid absorbed will be unaffected. Because linezolid has nearly complete oral absorption, this property makes it possible to transition from intravenous to oral therapy easily and without adversely affecting therapeutic levels of linezolid in patients who are being treated via a "step down" method¹⁵.

Distribution:

Linezolid has been shown to distribute widely throughout the tissues of the body, in part due to its balanced hydrophilic (polar) and lipophilic (nonpolar) characteristics. The binding of linezolid to plasma proteins is low (approximately 30%); thus, a substantial portion of the administered linezolid will be present as free drug. The distribution of linezolid throughout the body at these different dosing conditions reflects extensive penetration into tissues and is indicated by the volume of distribution at steady state (approximately equal to total body water).

Clinically significant levels of linezolid have been achieved in various tissues, including:

· Lung epithelial lining fluid

· Bronchial secretions

· Skin and soft tissues

· Bone

· Cerebrospinal fluid (moderate levels)

Therefore, the distribution profile of linezolid makes it appropriate for use in treating pneumoniae, complicated skin and skin structure infections, and some infections of the central nervous system¹⁵.

Metabolism:

In the liver, linezolid is mostly transformed (oxidized) by ways that do not involve enzymes (i.e., via a non-enzymatic pathway), which creates two inactive metabolites. This means that the majority of the metabolism of linezolid does not rely on cytochrome P450 (CYP450) enzymes for its metabolism. Thus, there is less potential for drug interactions through metabolism or variability in drug response due to genetic differences in cytochrome P450 enzyme function.

The fact that CYP450 does not significantly metabolize linezolid represents an important clinical benefit over many other antimicrobial agents¹⁵.

Elimination:

Linezolid is eliminated through both the kidneys and non-renal routes. About thirty percent (30%) of the dose given is excreted from the body intact via the kidneys, with the remaining seventy percent (70%) eliminated as inactive metabolites. The time it takes for half of the linezolid in the body to be removed (i.e., the terminal elimination half-life) is between 4.5 and 5.5 hours in healthy adult patients.

In patients with renal dysfunction, the levels of linezolid in the body may increase due to the accumulation of the inactive metabolites, but this should not have any significant impact on the total amount of parent drug remaining in the body. Linezolid is generally dosed the same in patients with mild-to-moderate renal dysfunction, but the patient should be monitored carefully if he or she has severe renal dysfunction or if treatment will be extended for many days¹⁵.

Pharmacodynamic Properties:

Linezolid demonstrates time dependent anti-bacterial action with its effectiveness tied to the duration of the drug in the regulator above the minimum inhibitory concentration (MIC) or the quantity of drug necessary to impede the growth of bacteria.

The PK/PD parameter known to correlate best with clinical outcomes is the area under the concentration curve/mic (AUC/MIC), with several studies having suggested correlation with successful therapeutic outcomes in Gram positive infections when the AUC/MIC ratio is maintained at greater than 80 and less than 120.

Unlike concentration dependent anti-bacterials like aminoglycosides where a higher peak concentration will lead to improvements in bactericidal function per unit increase in peak concentration, the importance of maintaining continuous therapeutic exposure is a greater indication of therapeutic utility of linzeolid versus objective measures of therapeutic utility based upon maximum peak plasma concentration¹⁶.

Dosing:

The standard dosage of linezolid for adult patients is 600 mg orally or intravenously every 12 hours; because equivalent pharmacokinetics exist for linezolid at therapeutic dosages or doses of greater than 600 mg per day in hepatic impaired patients, and mild to moderate renal impaired patients do not typically require any dose adjustment.

Therapeutic drug monitoring (TDM) has been proposed in certain situations for linezolid, including during prolonged therapy, in acutely ill patients, and where there is suspicion for toxicity; for these patients, monitoring trough concentrations will hopefully assist in preventing hematological adverse events, while optimally achieving antimicrobial treatment¹⁷.

Special populations:

Pharmaco-kinetics varies with age, especially in paediatrics where clearance rates are higher than adults. Therefore, pharmacokinetic parameters differ slightly between paediatric patients and adults and require weight-based drug dosing. Pharmacokinetics also changes minimally in elderly patients and most do not require a modified dose.

In patients receiving haemodialysis, partial linezolid is eliminated and consideration should be given to administering linezolid following dialysis to aid in maintaining appropriate levels of the drug¹⁷.

Clinical implications:

The pharmacokinetics of linezolid (e.g.: high oral bioavailability, distribution to body tissues, minimal involvement of the cytochrome P450 enzyme, predictable clearance) suggest linezolid is well suited for use in outpatient therapy and for step-down therapy due to the pharmacodynamics supporting a twice per day dosing regimen encouraging patient compliance^16,17.

6. Clinical Uses and Therapeutic Applications:

Linezolid has become a key therapy for the treatment of serious infections caused by multidrug-resistant Gram-positive bacteria. Its excellent oral bioavailability, predictable tissue penetration and unique mechanism of action make it particularly advantageous in both inpatient and outpatient environments. The majority of clinical uses of linezolid have been directed toward infections where the use of beta-lactam (e.g., penicillin) antibiotics and/or glycopeptide (e.g., vancomycin) antibiotics are limited due to resistant organisms.

Community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP):

Linezolid is approved as a treatment for both CAP and HAP (including ventilator-associated pneumonia) due to susceptible Gram-positive organisms. Linezolid has also shown good efficacy against methicillin-resistant Staphylococcus aureus (MRSA), which is the most common cause of severe nosocomial pneumonia (pneumonia acquired in a hospital setting).

Linezolid also provides higher and more stable concentrations in the lung epithelial lining fluid (the thin layer of fluid covering the inside of the lungs) than vancomycin. Several clinical studies have demonstrated at least comparable, and in some cases superior, clinical cure rates in MRSA pneumonia, with more pronounced superiority in patients with high vancomycin minimum inhibitory concentrations (MIC creep). The predictable degree of pulmonary penetration of linezolid contributes greatly to its overall efficacy¹⁸.

Complicated skin and soft tissue infections (cSSTIs):

Linezolid is frequently used to treat complicated skin and soft tissue infections caused by resistant Gram-positive bacteria (e.g., MRSA, Streptococcus spp.). In patients with these types of infections, linezolid is effective and well tolerated¹⁹.

Vancomycin-Resistant Enterococcal Infections:

Linezolid is one of the main treatment options available for infections caused by vancomycin-resistant enterococci including Enterococcus faecium. It is indicated for the treatment of VRE-related blood infections (bacteremia) and other systemic infections Linezolid’s mechanism of action (inhibition of protein synthesis via a different mechanism than those agents that act on the cell wall) enables linezolid’s continued effectiveness in treating VRE infections¹⁹.

Bloodstream Infections and Bacteremia:

Linezolid can be used in certain cases of gram-positive bacteremia, particularly when resistant Organisms are present and/or an individual cannot tolerate vancomycin. While theoretical concerns exist regarding the utility of linezolid’s bacteriostatic activity in blood infection, clinical data support the use of linezolid for specific circumstances, particularly when source control is achieved¹⁹.

Tuberculosis and Multidrug-Resistant Tuberculosis (MDR-TB):

Linezolid has demonstrated activity against Mycobacterium tuberculosis and is included as part of the treatment regimens for MDR-TB and extensive drug-resistant TB. Linezolid has dramatically improved treatment outcomes of MDR-TB. However, the long duration of therapy needed for TB also places people at higher risk for hematological and central nervous system toxicity therefore careful monitoring is essential.

Central Nervous System Infections:

Because of its moderate penetration of the cerebrospinal fluid, linezolid has been used for the treatment of certain patients with resistant gram-positive meningitis and ventriculitis when other agents cannot be used. Linezolid is an adjunctive treatment and is preferred to be used when necessary²².

Special Clinical Scenarios:

Use of linezolid has a number of advantages in certain specific clinical scenarios. These include:

· Patients who are being transitioned from IV to PO therapy

· Patients with renal dysfunction, where creatinine monitoring is difficult or unfeasible

· Patients who have a history of anaphylaxis with beta-lactams (also known as penicillin-based antibiotics)

· Patients whose infecting bacteria have a high MIC value for vancomycin

Due to its predictable pharmacokinetic properties and negligible metabolism by cytochrome P450, linezolid can be given safely with many commonly prescribed drugs²².

Comparison of Effectiveness:

Linezolid is an effective alternative for treating pulmonary infections (in conjunction with either daptomycin or vancomycin) because it has better penetration into lung tissues than either of these two agents. However, for life-threatening infections such as endocarditis (involving heart valves), bactericidal agents (such as daptomycin) will often be preferred. Factors that should be considered in determining therapy include susceptibility of pathogen, location of the infection, comorbidities for the patient, and possible adverse prescription effects.

Duration of Therapy:

Pneumonia and skin-related infections are generally treated for between 10 to 14 days. Prolonged therapy (greater than 14 days) may be required to treat more complicated infections, or in patients with underlying issues (such as on-going chronic tuberculosis or other infectious agents). When treating patients for longer than 14 days, they should be monitored closely for hematologic toxicities (through complete blood counts) and peripheral neuropathies²².

7. Safety Profile, Adverse Effects, and Drug-Drug Interactions:

Safety, Adverse Effects, Drug Interactions and Overall Profile Linezolid can produce significant adverse effects when used for long periods or when used off label. Most of the concerns result from the drug's off-target inhibition of the mitochondrial protein synthesis and the weak reversible inhibition of MAO (monoamine oxidase). Understanding these "off-targets" is critical to optimizing therapy and reducing toxicity.

Hematological Toxicity:

Myelosuppression Myelosuppression is the most common adverse effect linked with the use of linezolid. Thrombocytopenia is the most common, but anemia and leukopenia can occur as well. The frequency and severity of myelosuppression are generally dose- and duration-related, with individuals at increased risk of myelosuppression when treatment courses exceed 10 to 14 days.

The mechanism of action is thought to be related to inhibition of mitochondrial ribosomes in the bone marrow precursor cells. The bone marrow suppressive effect is generally reversible when the linezolid is discontinued. Close monitoring of complete blood count (CBC) is suggested for anyone who has received treatment for more than two weeks or who has a hx of hematologic disorder²³.

Peripheral and Optic Neuropathy:

Neuropathy Prolonged use (more than 28 days) of linezolid can lead to optic and peripheral neuropathy. Examples of symptoms include visual disturbances, paresthesias, and poor visual acuity. The mechanism of action is thought to be due to damage/inhibition of mitochondrial protein synthesis in the nervous system. Recognition of neuropathy while on linezolid is essential, as neuropathy may develop to a point of being irreversible if linezolid therapy continues²⁴.

Lactic Acidosis:

Cases of lactic acidosis after prolonged use (rare) have been reported, and lactic acidosis may occur due to mitochondrial toxicity leading to impaired oxidative phosphorylation and increased anaerobic metabolism. Signs of lactic acidosis can be nausea, vomiting, abdominal pain, and unexplained metabolic acidosis, and prompt discontinuation of therapy is necessary if lactic acidosis is suspected²⁵.

Gastrointestinal Effects:

Common mild side effects include nausea, diarrhea, vomiting, and headache; generally, these are self-limited and do not require therapy discontinuation²⁶.

Serotonin Syndrome:

Linezolid is considered a weak reversible inhibitor of MAO-A; this provides the potential to develop Serotonin Syndrome when linezolid is used in conjunction with serotonergic agents (SSRIs, SNRIs, certain antidepressants). Clinical signs/symptoms of serotonin syndrome include:

· Hyperthermia

· Agitation

· Tremor

· Hyperreflexia

· Autonomic Instability

A complete risk/benefit analysis should be performed before prescribing linezolid to patients taking serotonergic agents; either discontinuing the interacting agent for a short period of time or close monitoring may be necessary²⁷.

Hypertensive Reactions and Tyramine Interaction:

Due to MAO inhibition, linezolid can enhance the hypertensive effects of sympathomimetic agents and foods rich in tyramine. In theory, consuming large amounts of tyramine may cause hypertensive episodes, but hypertension-related reactions at recommended dosage ranges occur infrequently. Therefore, patients should be counselled to limit their consumption of aged cheeses, fermented products and certain other high-tyramine foods while on treatment with linezolid²⁸.

Renal and Hepatic Considerations:

Linezolid does not have to be routinely dose adjusted in cases of mild to moderate renal or hepatic impairment; however, with severe renal impairment, inactive metabolites could accumulate. Although little evidence suggests these inactive metabolites contribute greatly to linezolid toxicity, patients receiving linezolid over long periods of time should be monitored²⁹.

Risk Factors for Toxic Reactions:

Risk factors for toxicity include:

· Being treated for > 14 days

· Having high systemic exposure (i.e., high trough levels)

· Having renal impairment

· Being > 65 years old

· Receiving concomitant serotonergic therapy.

Therapeutic drug monitoring (TDM) is a strategy to increase exposure and to prevent hematological toxicity in high-risk populations³⁰.

Safety Compared to Other Oxazolidinones:

New oxazolidinones (Tedizolid) are designed to provide antibacterial activity while possibly decreasing mitochondrial toxicity and bone marrow suppression. Some comparative studies suggest that decreasing treatment duration and dosage will decrease the frequency of adverse events; however, data regarding long-term safety is not available³¹.

8. Resistance Mechanisms and Molecular Epidemiology:

Since its clinical use began in 2000, linezolid had been associated with a low rate of resistance; however, reports of resistant isolates have increased significantly in the last eleven years. Although resistance to linezolid remains infrequent when compared to resistance rates in other classes of antibiotics, the development of such resistant organisms poses significant therapeutic threats because linezolid is generally only administered for use against multidrug-resistant Gram-positive organisms.

23S rRNA Gene Mutations:

The best-understood mechanism for resistance involves mutations at point mutations/as part of domain V of the gene that codes for the 23S rRNA that is the site on the 50S ribosome where linezolid binds.

A good example of a mutation affecting linezolid's capacity to bind is an alteration in the configuration of the peptidyl transferase centre caused by a G2576T mutation (based on the ESCHERICHIA COLI numbering system) will decrease the binding affinity of the drug to the ribosome.

In addition, many organisms (such as bacteria that produce the 23S rRNA) have multiple copies of the 23S rRNA gene, meaning that the degree of resistance to a drug can be determined by the number of mutated alleles/identities present.

Furthermore, the accumulation of mutations through numerous sequential accumulation steps eventually results in a higher MIC level for an organism.

Both of these scenarios have occurred with methicillin-resistant staphylococcus aureus and vancomycin-resistant enterococci exhibiting resistance after being treated with linezolid for long periods of time³¹.

cfr Gene–Mediated Resistance:

Concerns have arisen regarding the dissemination of the plasmid-mediated cfr (chloramphenicol–florfenicol resistance) gene in recent years as it is responsible for the development of resistance against chloramphenicol. The cfr gene encodes a methyltransferase that methylates the A2503 adenine residue within the 23S rRNA, which alters its ribosomal binding site and reduces susceptibility to not only linezolid but multiple other classes of antibiotics that bind to the peptidyl transferase center.

This mechanism confers a multidrug resistance phenotype responsible for resistance to:

· Oxazolidinones

· Penicols

· Lincosamides

· Pleuromutilins

· Streptogramin A

The cfr gene is located on plasmids and allows for horizontal gene transfer between different species of bacteria, which raises concerns about the rapid dissemination of cfr within hospital environments³³.

Mutations of the Ribosomal Proteins:

Mutations in the ribosomal proteins L3 and L4 next to the binding site of linezolid have also contributed to resistance development. Mutations in these specific ribosomal proteins may have an indirect impact on the formation of the peptidyl transferase region, leading to decreased binding of the drug.

Ribosomal protein mutations are not quite as common as mutations in the 23S rRNA and mutations that are mediated by the cfr gene, but collectively they do contribute to modestly increased MIC values³².

Efflux Pump Mechanisms:

Efflux-mediated resistance mechanisms have been described for some Gram-positive organisms. Increased activity of efflux transporters will result in lower intracellular levels of linezolid and therefore less effective interaction with the target. However, in terms of overall contribution to linezolid resistance mechanisms, efflux is of minor importance as compared to mutations in target sites.

Epidemiology:

Globally, resistance rates are generally low (< 2-3%) in most regions; however, there are isolated outbreaks of linezolid-resistant MRSA and enterococci, primarily in tertiary care hospitals and ICU settings due to the greater use of antibiotics over an extended period of time.

Factors associated with the development of resistance include:

· The use of antibiotics over a long period of time

· The use of suboptimal amounts of antibiotic

· Infections caused by numerous organisms

· Lack of sufficient infection prevention and control practices

The dissemination of clinically relevant cfr-positive isolates has been documented in both clinic and agricultural settings, thus establishing the need for antimicrobial stewardship within both human and veterinary medicine.

Clinical Significance:

The development of linezolid resistance reduces the number of treatment options available for patients with Gram-positive (GP) infections caused by Multidrug-resistant (MDR) organisms. The availability of resources to detect linezolid resistance early via both susceptibility testing and molecular diagnostic methods will allow clinicians to manage patients’ therapy appropriately once their cultures return and confirm resistance to the linezolid compound. In some instances of proven linezolid resistance, alternative agents such as newer oxazolidinones and other agents active against GP organisms may need to be utilized to treat infections successfully.

From the public health standpoint, it is imperative that continuous surveillance be performed on the development of resistance, that dosing strategies are optimized based upon pharmacokinetic/pharmacodynamic principles and that antimicrobial stewardship programs are implemented in order to preserve the future utility of linezolid.

9. Comparative Assessment of the Oxazolidinone Family and Potential New Derivatives:

Martin's clinical success of linezolid proved the Oxazolidinone scaffold to be a valid basis for making antibacterial drugs. Still there have been concerns regarding drug toxicity (primarily on blood), causing inhibition of mitochondria and the emergence of new resistant strains of bacteria prompted the development of new generations of oxazolidinones with better activity and more safety. Therefore, a comparison among the members of this family will provide invaluable data for the purpose of understanding structure-activity optimization and the best place to fit these agents in the therapy equation.

Tedizolid (second generation oxazolidinone):

Tedizolid is a second generation Oxazolidinone created to correct many of the shortcomings of linezolid. The major structural differences of Tedizolid versus linezolid are located at both the C- and D-rings which provide for a greater binding affinity to the 23S rRNA target site. These structural improvements also provide for superior in vitro potency against both Gram-positive pathogens including MRSA and certain linezolid resistant pathogens.

Tedizolid possess:

· Superior intrinsic antibacterial activity (lower MIC values)

· Single daily dosing due to longer half-life

· Shorter standard duration of therapy (typically 6 days for treating skin infections)

· Potentially a lower risk for myelosuppression (bone marrow suppression) when receiving shorter courses of therapy.

Tedizolid acts by the same general method of action as linezolid by preventing the formation of the 70S initiation complex that is critical for protein synthesis. However, improved ribosomal binding may increase the activity of Tedizolid against bacteria that are resistant to other agents through CFR, although there may be some cross-resistance.

Comparison of Efficacy Between Tedizolid and Linezolid:

Based upon relative potency, tedizolid achieved greater efficacy with lower minimum inhibitory concentrations (MICs) than linezolid. For both agents, the most common pharmacokinetic/pharmacodynamic parameters used to predict efficacy was the ratio of area under the concentration-time curve (AUC) to the minimum inhibitory concentration (MIC). In addition, tedizolid has an extended half-life, permitting once daily dosing; therefore, it may offer better patient compliance and make therapy easier to use than twice daily dosing of linezolid.

Although there is a significant history with use of linezolid for treatment (many years of clinical use) and broadest indication (including treatment of pneumonia and VRE [vancomycin resistant enterococcus] infection), the development of both tedizolid and linezolid includes the consideration of minimizing mitochondrial toxicity as a key reason to develop both compounds. Data suggest that there is a lower incidence of thrombocytopenia from short-course tedizolid therapy than from either short- or long- course linezolid therapy; however, limited long-term safety data on tedizolid are available, while linezolid has well-characterized long-term adverse effects after years of use.

Both compounds also display the potential for drug interactions via MAO inhibition; however, under normal dosing regimens, tedizolid may display a lower propensity to exhibit serotonergic drug interactions than linezolid³⁴.

Resistance Mechanisms to Newer Oxazolidinones:

Structural modifications to the second generation of oxazolidinones were intended to improve binding affinity to bacteria with certain 23S rRNA mutations that confer resistance against older agents; however, some mechanisms of resistance, including cfr-mediated methylation, can confer cross-resistance across the entire class of drugs. As a result, many newer derivatives have been developed to provide optimal antibacterial activity in the presence of these resistance mechanisms. As more resistance mechanisms are identified in addition to the ones currently known (e.g., CFR) and as third and fourth^ generation compounds are developed, we can expect the treatment of resistant infections to become increasingly problematic.

10. Adverse Effects, Toxicity, and Safety Profile of Linezolid:

Linezolid has been considered relatively safe as an antimicrobial agent for short-term administration. However, the adverse effects associated with this agent become more prominent over time, especially after 10-14 days of therapy. Linezolid is commonly used for more complex infections, like methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), osteomyelitis, and multi-drug resistant tuberculosis (MDR-TB), and therefore, it is important to know about potential adverse reactions in order to optimize safety and effectiveness for patients treated with linezolid.

Hematologic Toxicity:

The most clinically significant adverse reaction to linezolid is reversible myelosuppression, particularly thrombocytopenia, which is usually dose dependent. This myelosuppression occurs most frequently in patients who have been treated with linezolid for more than two weeks. The mechanism of myelosuppression may be related to linezolid's inhibition of mitochondrial protein synthesis in hematopoietic precursor cells. There is a similarity between mitochondrial ribosomes and the bacterial 70s ribosome in terms of structure; this may explain why linezolid interferes with the translation of mitochondrial ribosomes, leading to decreased production of energy in the cell and suppression of bone marrow function.

Clinically, thrombocytopenia, anemia, leukopenia and, very rarely, pancytopenia can occur. The incidence and severity of these hematologic complications will be higher in those patients with renal failure, long duration of therapy, severely ill patients, or receiving additional myelosuppressive medications. It should be noted that hematologic complications typically resolve after discontinuation of linezolid therapy. Current clinical guidelines recommend monitoring complete blood counts (CBC) weekly in patients receiving prolonged linezolid therapy²⁴.

11. Clinical Resistance Patterns and Emerging Challenges:

Resistance to Linezolid has risen as a global issue, despite an initial belief that it would have a low potential for resistance due to its unique mechanism of action. Though not as frequent as the emergence of resistance to other classes of antibiotics, it continues to limit the best practice option of therapy when treating multidrug-resistant Gram-positive infections³⁵.

Resistance Mechanisms:

Mutation of the 23S rRNA gene located on the 50S ribosomal subunit is the predominant mechanism for developing resistance to Linezolid. Mutations alter the binding site of Linezolid in the peptidyl transferase center and reduce drug affinity to the binding site, thus diminishing the drug's ability to inhibit protein synthesis. Since many bacteria possess multiple copies of the 23S rRNA gene, the number of copies of mutated 23S rRNA correlates to the level of resistance to Linezolid.

The gene, cfr, is another critical mechanism of resistance to Linezolid. The cfr gene encodes a methyltransferase that adds a methyl group to the adenine residues within the 23S rRNA, granting resistance to Linezolid, in addition to multiple other classes of antibiotics, creating a combined PhLOPSA phenotype (i.e., phenicols, lincosamides, oxazolidinones, pleuromutilins, streptogramin A). The fact that cfr is found on plasmids raises concerns of horizontal gene transfer and horizontal gene transfer between bacterial species. Recently, other resistance determinants such as optrA and poxtA have also emerged³⁵.

Figure 3: Mechanisms of Resistance³⁵

12. Novel Formulations, Derivatives, and Future Perspectives:

The increasing clinical use of Linezolid in treating multidrug resistant Gram-positive infections has created an impetus for research to improve upon the existing oxazolidinones and develop new derivatives with better properties. While linezolid was the first approved oxazolidinone for clinical use, it has limitations related to side effects such as mitochondrial toxicity, myelosuppression, neuropathy, and the emergence of resistance, which led researchers to develop next generation oxazolidinone compounds.

Structural Optimization and Second-Generation Oxazolidinones:

Rational drug design methods have been used to alter the oxazolidinone pharmacophore by increasing ribosomal binding affinity and reducing off-target interactions with mitochondria. A good example of this is Tedizolid. Structural modifications were made to Tedizolid to improve potency against resistant Gram-positives, including some linezolid-resistant strains, along with the aforementioned benefits of once-daily dosing, shorter treatment duration, and possibly reduced hematological toxicity because of less mitochondrial inhibition.

Investigational oxazolidinones are also being investigated with structural modifications aimed at improving pharmacokinetic characteristics, increasing activity against cfr-mediated resistant strains, and improving safety margins. These modifications are predominantly achieved by modifying the substitutions on the aromatic ring system to enhance the interactions of the compound within the peptidyl transferase center of the 50S ribosomal subunit³⁷.

Strategies to Overcome Resistance:

Resistance is now emerging via mutational change in 23S rRNA or transferable resistance genes such as cfr, optrA and poxtA and this has initiated molecular studies to design agents which can retain activity in the presence of ribosomal methylation or protective protein expressions. Through cryo-electron microscopy and 3D structural modeling studies, the modifications of ribosomal binding sites leading to resistance have been elucidated and will aid the rational design of agent development through the design of new compounds based on knowledge gained through these studies.

Combination therapies are being studied to treat multidrug-resistant tuberculosis, and biofilm-associated infections that do not respond to traditional therapies. The selection of synergistic combinations from different classes of antimicrobials may help decrease the selective pressure and delay the emergence of resistance³⁷.

Advanced Drug Delivery Systems:

Numerous novel formulation strategies are now being studied for their potential to greatly enhance therapeutic outcomes. These approaches include:

· Liposomal encapsulation, which allows for targeted drug delivery and reduces total body exposure to the drug, thereby decreasing the possibility of systemic toxicity.

· Nanoparticle-based sustained-release systems, which can provide a controlled release of drug over an extended period of time.

· Localized delivery systems designed specifically for treating infections associated with orthopedic implants or joint replacements.

· Inhalation-based formulations for targeted pulmonary delivery.

These strategies are focused on optimizing drug levels at the desired local tissue site while minimizing the total dose to limit the likelihood of adverse events.

Pharmacogenomics and Personalized Therapy:

Pharmacogenomic advancements may further refine linezolid therapy. Genetic variation in either mitochondrial function or drug metabolism may affect a patient's susceptibility to drug-related adverse events such as myelosuppression or neuropathy. In the future, personalized medicine approaches may involve biomarker-guided dosing techniques to enhance safety³⁸.

Expanding Clinical Applications:

The use of linezolid continues to be a significant component of the treatment of multidrug-resistant tuberculosis, particularly in patients with extensively drug-resistant (XDR) tuberculosis. There are currently several clinical trial studies evaluating the use of optimized dosing regimens for linezolid that will balance the efficacy of the drug as an antimicrobial agent against the toxicity of the drug. Additionally, linezolid's role in the treatment of other complex infections such as prosthetic joint or central nervous system infections is being investigated⁴.

Future Directions: Future research priorities include:

· Development of oxazolidinones with reduced levels of mitochondrial toxicity

· Enhanced global surveillance of the patterns of resistance to linezolid

· Structural refinement to overcome plasmid-mediated resistance to linezolid

· Investigating the potential of combination therapies to reduce the risk of developing resistance to linezolid.

13. Conclusion and Clinical Perspectives:

Linezolid is the first clinically approved oxazolidinone antibiotic effective against multidrug-resistant Gram-positive bacteria such as MRSA, VRE, and multidrug-resistant Mycobacterium tuberculosis. It inhibits bacterial protein synthesis by binding to the 23S rRNA of the 50S ribosomal subunit, resulting in minimal cross-resistance with other antibiotics.

The drug has excellent oral bioavailability and good tissue penetration, especially in the lungs, making it useful in pneumonia, skin infections, osteomyelitis, bloodstream infections, and multidrug-resistant tuberculosis. SAR studies show that modifications in its aromatic ring and morpholine moiety influence its activity and toxicity.

Although linezolid is highly effective, prolonged use may cause adverse effects such as myelosuppression, lactic acidosis, neuropathy, and monoamine oxidase–related drug interactions. Careful monitoring is therefore necessary during therapy.

Emerging resistance due to cfr, optrA, and poxtA genes highlights the need for antimicrobial stewardship and continuous surveillance. Compared with Vancomycin, Daptomycin, and Tedizolid, linezolid remains important for pulmonary infections and oral treatment options. Future developments focus on personalized therapy, combination treatment, and newer oxazolidinones to improve safety and reduce resistance.

REFERENCES:

1. Cerceo E, Deitelzweig SB, Sherman BM, Amin AN. Multidrug-resistant gram-negative bacterial infections in the hospital setting: overview, implications for clinical practice, and emerging treatment options. Microbial Drug Resistance. 2016 Jul 1; 22(5): 412-31.

2. Georgopapadakou NH. Penicillin-binding proteins and bacterial resistance to beta-lactams. Antimicrobial Agents and Chemotherapy. 1993 Oct; 37(10): 2045-53.

3. Shaw KJ, Barbachyn MR. The oxazolidinones: past, present, and future. Annals of the New York Academy of Sciences. 2011 Dec; 1241(1): 48-70.

4. Hashemian SM, Farhadi T, Ganjparvar M. Linezolid: a review of its properties, function, and use in critical care. Drug Design, Development and Therapy. 2018 Jun 18: 1759-67.

5. Matsingos C, Al-Adhami T, Jamshidi S, Hind C, Clifford M, Sutton JM, Rahman KM. Synthesis, microbiological evaluation and structure activity relationship analysis of linezolid analogues with different C5-acylamino substituents. Bioorganic & Medicinal Chemistry. 2021 Nov 1; 49: 116397.

6. Ford CW, Zurenko GE, Barbachyn MR. The discovery of linezolid, the first oxazolidinone antibacterial agent. Current Drug Targets-Infectious Disorders. 2001 Aug 1; 1(2): 181-99.

7. Leach KL, Brickner SJ, Noe MC, Miller PF. Linezolid, the first oxazolidinone antibacterial agent. Annals of the New York Academy of Sciences. 2011 Mar; 1222(1): 49-54.

8. Tan TQ, Yogev R. Clinical pharmacology of linezolid: an oxazolidinone antimicrobial agent. Expert Review of Clinical Pharmacology. 2008 Jul 1; 1(4): 479-89.

9. Gan WC, Ng HF, Ngeow YF. Mechanisms of linezolid resistance in mycobacteria. Pharmaceuticals. 2023 May 24; 16(6): 784.

10. Yuan Y, Li J, Chen Y, Cai Q, Xu Y, Lin L, Lang Y, Guo S, Zhang R, Cai X. Mechanism underlying linezolid-induced peripheral neuropathy in multidrug-resistant tuberculosis. Frontiers in Pharmacology. 2022 Sep 9; 13: 946058.

11. Long KS, Vester B. Resistance to linezolid caused by modifications at its binding site on the ribosome. Antimicrobial Agents and Chemotherapy. 2012 Feb; 56(2): 603-12.

12. Mendes RE, Deshpande L, Streit JM, Sader HS, Castanheira M, Hogan PA, Flamm RK. ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries. Journal of Antimicrobial Chemotherapy. 2018 Jul 1; 73(7): 1880-7.

13. Noskin GA, Siddiqui F, Stosor V, Hacek D, Peterson LR. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrobial Agents and Chemotherapy. 1999 Aug 1; 43(8): 2059-62.

14. Sweeney MT, Zurenko GE. In vitro activities of linezolid combined with other antimicrobial agents against staphylococci, enterococci, pneumococci, and selected gram-negative organisms. Antimicrobial Agents and Chemotherapy. 2003 Jun; 47(6): 1902-6.

15. Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. Journal of Antimicrobial Chemotherapy. 2011 May 1; 66(suppl_4): iv7-15.

16. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. Journal of Antimicrobial Chemotherapy. 2003 May 1; 51(suppl_2): ii17-25.

17. Stein GE, Schooley SL, Peloquin CA, Kak V, Havlichek DH, Citron DM, Tyrrell KL, Goldstein EJ. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Annals of Pharmacotherapy. 2005 Mar; 39(3): 427-32.

18. Mandell LA. Community-acquired pneumonia: an overview. Postgraduate Medicine. 2015 Nov 2; 127(6): 607-15.

19. Peppard WJ, Weigelt JA. Role of linezolid in the treatment of complicated skin and soft tissue infections. Expert Review of Anti-Infective Therapy. 2006 Jun 1; 4(3): 357-66.

20. Murray BE. Vancomycin-resistant enterococcal infections. New England Journal of Medicine. 2000 Mar 9; 342(10): 710-21.

21. Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S. Linezolid in the treatment of multidrug-resistant tuberculosis. Clinical Infectious Diseases. 2010 Jan 1; 50(1): 49-55.

22. Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. Annals of Pharmacotherapy. 2007 Feb; 41(2): 296-308.

23. Cattaneo D, Marriott DJ, Gervasoni C. Hematological toxicities associated with linezolid therapy in adults: key findings and clinical considerations. Expert Review of Clinical Pharmacology. 2023 Mar 4; 16(3): 219-30.

24. Narita M, Tsuji BT, Yu VL. Linezolid‐associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2007 Aug; 27(8): 1189-97.

25. Mao Y, Dai D, Jin H, Wang Y. The risk factors of linezolid-induced lactic acidosis: a case report and review. Medicine. 2018 Sep 1; 97(36): e12114.

26. Clemett D, Markham A. Linezolid. Drugs. 2000 Apr; 59(4): 815-27.

27. Wigen CL, Goetz MB. Serotonin syndrome and linezolid. Clinical infectious diseases. 2002 Jun 15; 34(12): 1651-2.

28. Antal EJ, Hendershot PE, Batts DH, Sheu WP, Hopkins NK, Donaldson KM. Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine. The Journal of Clinical Pharmacology. 2001 May; 41(5): 552-62.

29. Liu J, Pang Y, Li W, Sun J, He Y, Guo Y, Dong J. Impact of hepatic impairment and renal failure on the pharmacokinetics of linezolid and its metabolites: contribution of hepatic metabolism and renal excretion. Antimicrobial Agents and Chemotherapy. 2025 May 7; 69(5): e01892-24.

30. Kishor K, Dhasmana N, Kamble SS, Kumar Sahu R. Linezolid induced adverse drug reactions-an update. Current Drug Metabolism. 2015 Sep 1; 16(7): 553-9.

31. Douros A, Grabowski K, Stahlmann R. Drug–drug interactions and safety of linezolid, tedizolid, and other oxazolidinones. Expert Opinion on Drug Metabolism & Toxicology. 2015 Dec 2; 11(12): 1849-59.

32. Meka VG, Pillai SK, Sakoulas G, Wennersten C, Venkataraman L, DeGirolami PC, Eliopoulos GM, Moellering Jr RC, Gold HS. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. The Journal of Infectious Diseases. 2004 Jul 15; 190(2): 311-7.

33. Morales G, Picazo JJ, Baos E, Candel FJ, Arribi A, Peláez B, Andrade R, de la Torre MÁ, Fereres J, Sánchez-García M. Resistance to linezolid is mediated by the Cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clinical Infectious Diseases. 2010 Mar 15; 50(6): 821-5.

34. Feng J, Xiang F, Cheng J, Gou Y, Li J. Comparative efficacy and safety of vancomycin, linezolid, tedizolid, and daptomycin in treating patients with suspected or proven complicated skin and soft tissue infections: an updated network meta-analysis. Infectious Diseases and Therapy. 2021 Sep; 10(3): 1531-47.

35. Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries RM. The emerging problem of linezolid-resistant Staphylococcus. Journal of Antimicrobial Chemotherapy. 2013 Jan; 68(1): 4-11.

36. Lucian-Daniel, P., Andreea-Eliza, Z., Nicoleta-Maricica, M., Cosmin-Răducu, R., Elena-Roxana, M., Alice-Crina, C., Bianca-Ioana, C., Dana, T., Oana-Maria, D., Liliana, M.T. and Gabriela, G. Methicillin-Resistant Staphylococcus aureus (MRSA) and Vancomycin-Resistant Enterococci (VRE) in Nosocomial Infections: A Systematic Review of Resistance, Pathogenesis, and Clinical Management. Microorganisms. 2026; 14(2):428.

37. Zhao Q, Xin L, Liu Y, Liang C, Li J, Jian Y, Li H, Shi Z, Liu H, Cao W. Current landscape and future perspective of oxazolidinone scaffolds containing antibacterial drugs. Journal of Medicinal Chemistry. 2021 Jul 14; 64(15): 10557-80.

38. Cheli S, Fusi M, De Silvestri A, Bonini I, Clementi E, Cattaneo D, Montrasio C, Baldelli S. In linezolid underexposure, pharmacogenetics matters: the role of CYP3A5. Biomedicine & Pharmacotherapy. 2021 Jul 1; 139: 111631.

Received on 06.05.2026 Revised on 27.05.2026

Accepted on 15.06.2026 Published on 04.07.2026

Available online from July 30, 2026

Asian J. Research Chem.2026; 19(4):377-390.

DOI: 10.52711/0974-4150.2026.00057

This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License. Creative Commons License.